The magistral phage

Viruses

Volumn 10, Issue 2, 2018, Pages

  Pirnay, Jean Paul ^a   Verbeken, Gilbert ^a   Ceyssens, Pieter Jan ^b   Huys, Isabelle ^c   de Vos, Daniel ^a   Ameloot, Charlotte ^d   Fauconnier, Alan ^d,e  

^a QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Federal Agency for Medicines and Health Products Belgium   (Belgium)

^e Culture In Vivo ASBL   (Belgium)

Author keywords

Antibiotic; Antimicrobial resistance; Compounding pharmacy; Magistral preparation; Personalized medicine; Phage therapy; Regulatory framework

Indexed keywords

PRESCRIPTION DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL OVERGROWTH; BACTERIOPHAGE; DRUG COST; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; PHAGE THERAPY; REIMBURSEMENT; WESTERN MEDICINE; BELGIUM; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMICS; HEALTH CARE POLICY; PHYSIOLOGY; PROCEDURES; STANDARDS;

ANTI-INFECTIVE AGENTS; BACTERIOPHAGES; BELGIUM; DRUG DISCOVERY; DRUG INDUSTRY; HEALTH POLICY; HUMANS; PHAGE THERAPY;

EID: 85041865372     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v10020064     Document Type: Article

References (11)

1. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance. 2016 Release. Available online: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf (accessed on 4 February 2018).
2. United Nations. Draft Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance (16-16108 (E)). 2016 Release. Available online: http://www.un.org/pga/71/wpcontent/uploads/sites/40/2016/09/DGACM_GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108E.pdf (accessed on 17 December 2017).
3. Thiel, K. Old dogma, new tricks—21st Century phage therapy. Nat. Biotechnol. 2004, 22, 31–36. [CrossRef] [PubMed]
4. Hall, A.R.; De Vos, D.; Friman, V.P.; Pirnay, J.P.; Buckling, A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol. 2012, 78, 5646–5652. [CrossRef] [PubMed]
5. Jennes, S.; Merabishvili, M.; Soentjens, P.; Pang, K.W.; Rose, T.; Keersebilck, E.; Soete, O.; François, P.M.; Teodorescu, S.; Verween, G.; et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—A case report. Crit. Care 2017, 21, 129. [CrossRef] [PubMed]
6. Schooley, R.T.; Biswas, B.; Gill, J.J.; Hernandez-Morales, A.; Lancaster, J.; Lessor, L.; Barr, J.J.; Reed, S.L.; Rohwer, F.; Benler, S.; et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii Infection. Antimicrob. Agents Chemother. 2017, 61, e00954-17. [CrossRef] [PubMed]
7. Pirnay, J.P.; De Vos, D.; Verbeken, G.; Merabishvili, M.; Chanishvili, N.; Vaneechoutte, M.; Zizi, M.; Laire, G.; Lavigne, R.; Huys, I.; et al. The phage therapy paradigm: Prêt-à-porter or sur-mesure? Pharm. Res. 2011, 28, 934–937. [CrossRef] [PubMed]
8. Servick, K. Beleaguered phage therapy trial presses on. Science 2016, 352, 1506. [CrossRef] [PubMed]
9. ◦ 12911). 2016 Release. Available online: https://www.dekamer.be/doc/CCRA/pdf/54/ac464.pdf (accessed on 17 December 2017).
10. Fauconnier, A. Guidelines for Bacteriophage Product Certification. Methods Mol. Biol. 2018, 1693, 253–268. [PubMed]
11. Fauconnier, A. Regulating phage therapy: The biological master file concept could help to overcome regulatory challenge of personalized medicines. EMBO Rep. 2017, 18, 198–200. [CrossRef] [PubMed]